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A B S T R A C T
Longitudinal studies of newly diagnosed epilepsy in children and adults have identiﬁed prognostic
factors that allow early identiﬁcation of patients whose seizures are likely to remain uncontrolled with
antiepileptic medication. Results from outcome studies may be subject to bias, depending on the setting
(community versus clinic), design (retrospective versus prospective) and characteristics of the patient
cohort studied (age, types of epilepsy, speciﬁc comorbidities). Nevertheless, factors such as early
response to medication, underlying aetiology, and number of seizures prior to initiation of treatment
have consistently been found to be predictive of seizure outcomes. Other variables such as age,
electroencephalographic ﬁndings and the presence or absence of psychiatric co-morbidities have been
correlated with outcomes in some analyses. This review has examined studies of seizure outcomes in
adults and children with newly diagnosed epilepsy identifying the risk factors that are associated with
subsequent refractory epilepsy.
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Epilepsy, the tendency to have recurrent unprovoked seizures,
is the most common serious neurological disorder. Its prevalence
ranges from 0.5 to 1% of the population in developed countries, and
is probably higher in developing countries.1 This condition is,
however, merely a symptom of a wide variety of neurological
disorders, ranging from self-limiting and benign to devastating and
fatal. Regardless of the aetiology, the tendency to suffer recurrent
seizures exposes persons with epilepsy to a variety of physical,
psychological and social morbidities.2 Complete control of seizures
can negate these consequences to a large extent.3 The majority of
patients diagnosed with epilepsy can expect to achieve good
control of seizures with antiepileptic drug (AED) therapy,4,5 but a
substantial minority will continue to experience seizures in spite of
a range of AEDs used in adequate doses either singly or in
combination.6 Some patients whose seizures prove difﬁcult to
treat could beneﬁt from non-pharmacological strategies, especially
epilepsy surgery, which still remains one of the most underutilised
effective treatment modalities worldwide.7,8 Early identiﬁcation of
patients whose seizures are likely to be pharmacoresistant would
permit them to be offered referral for epilepsy surgery at the most
appropriate juncture.9* Corresponding author at: Epilepsy Unit, Western Inﬁrmary, Glasgow G11 6NT,
Scotland, UK. Tel.: +44 141 211 2534; fax: +44 141 211 2072.
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This short review will attempt to summarise data from relevant
studies of outcomes in newly diagnosed epilepsy in paediatric and
adult populations. These were identiﬁed from Pubmed using the
search terms ‘newly diagnosed epilepsy and outcomes’ and ‘newly
diagnosed epilepsy and prognosis’. Search results were reviewed
manually to identify relevant publications. All studies with a
minimum of 100 patients, who were followed up for at least 2
years, were included in this review (see Tables 1 and 2).
Results from studies of prognosis of epilepsy are often
conﬂicting. Some of the variability can be explained on the basis
of differences in populations and methodologies. As the underlying
cause of epilepsy can be widely varied, data from studies that
‘lump’ together all epilepsy types will be skewed in favour of those
most frequent in the population. Studying well-deﬁned epilepsy
(electroclinical) syndromes separately can provide better prog-
nostic information, but accurate classiﬁcation is not always
achievable even in patients attending specialist services. Studies
based in specialist clinics can be expected to have better
characterised patient groups, but may be biased towards the
more severe epilepsies. Retrospective studies, especially those
from specialist clinics, may not include patients with milder forms
of epilepsy.
Studies that identify all persons with new onset epilepsy in a
deﬁned population over a ﬁxed period of time and follow them up
prospectively will have the least recruitment bias. However,
identifying all cases can be challenging and the diagnosis may bender CC BY-NC-ND license.
Table 1
List of studies of outcomes in adult epilepsy. Studies from the same population have been grouped together. Studies marked with * (asterix) also inlcuded children.
Study Recruitment
period
Inclusion
criteria
Exclusion
criteria
Type of study Setting n Epilepsy
type
Follow up Method of
follow-up
n with
outcome
Outcomes Prognostic
factors identiﬁed
Annegers
et al.13
1935–74 >2 seizures not
provoked by an
acute cause
followed for
minimum of 5
years
Febrile and
other provoked
seizures
Retrospective Community 618 Mixed 5–20 years Chart review 457 5year remission Perinatal insult
causing physical and
intellectual handicap
worst outcomes (46%
remission)
Single seizures 65% by 10years Post natal acquired
epilepsy and idiopathi
epilepsy 74% remission
76% by 20years
Elwes
et al.15
Not stated Previously
untreated
epilepsy
None stated Prospective Clinic 106 Mixed 6–106
month
Clinical
review
106 82% 2 year sf
periods by 8 years
of fu
Poor prognosis
associated with
35% immediate
responders
Partial seizures
28% SF
throughout
High frequency of
tonic-clonic seizures
before
treatment
A neurologic, social, or
psychiatric handicap
A family history of
epilepsy
Collaborative
group18
1982 Previously
untreated
afebrile
seizures
AEDs started >3
months
before
enrolment
Prospective Clinic 280 Mixed 48
(median)
6 monthly
review
228 1–year remission
62% at 1 year, 81%
by 2
Remission less likely
with multiple seizure
types, higher number
of seizures before
treatment
Polytherapy as
initial
treatment
Years, 92% by 3
years, and 98% by
5 years
Number of seizures in
the ﬁrst year of AED
treatment correlated
with risk of refractory
epilepsy
Prophylactic use
of AEDs
3–year remission
92% 5 year
remission 78%
Provoked
seizures
22.1% not SF on
monotherapy
Cockerell
et al.*23
1984–87 Deﬁnite
epilepsy as
judged
by panel
Expert panel
disagree with
diagnosis of
epilepsy
Prospective Community 1091 Mixed 6 years Contact primary
care physician
5 year
remission
Age and seizure type
no effect on outcomes
Cockerell et al.*24 564 deﬁnite
epilepsy
9 years Idiopathic
seizures 69%
Children lower
remission rates
than adults
MacDonald*25 228 - probable
epilepsy
12 years Remote
symptomatic
epilepsy 61%
Partial seizures
worse than
generalised ones
Stephen
et al.33
1984–97 Newly
diagnosed
localisation
related peilepsy
None stated Retrospective Clinic 550 Localisation
reltated
epilepsy
Median
5 (2–15)
Chart review 550 No difference
between
cryptogenic and
symptomatic LRE
MTS worse than other
causes of LRE
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But 30% were
already on
treatement
Seizure free rates
worse for MTS
42%
AVM 78%
Infarction 63%
Primary brain
tumour 57%
Cortical Gliosis
57%
Cerebral atrophy
55%
Cortical dysplasia
54%
Kwan &
Brodie80
1984–1997 Newly
diagnosed
epilepsy
None Prospective Clinic 629 Mixed 5 years
(range 2–16)
Chart review 525 Refractory
epilepsy more
likely in
Poor prognosis
associated with
Symptomatic /
cryptogenic (40%)
than idiopathic
(26%)
Higher number of
seizures and poor
response to initial
monotherapy
More than 20
pretreatment
seizures
(51% v/s 29%)
47% seizure free
on ﬁrst AED
14% on second or
3rd AED
3% seizure free on
combination
therapy
Hitiris
et al.66
1981–2001 New diagnosis
of epilepsy
None Retrospective Clinic 890 Mixed 79 months
median
Chart review 780 59.2% seizure free
for at least 12
months
Uncontrolled epilepsy
associated with
Mohanraj &
Brodie67
More than 10 seizures
prior to starting
treatment
Family history of
epilepsy
History of febrile
seizures
Post-traumatic
epilepsy
Recreational drug use
Prior or current
psychiatric
comorbidity
Factors not predicting
poorer outcome
included gender,
neurological deﬁcit
and mental
retardation.
Del Felice
et al.*88
1989–99 Newly
diagnosed
epilepsy
None stated Retrospective Clinic 352 Mixed Upto 10 years Chart review 352 23.0% achieved
early remission
(immediate
seizure control
after start of AED)
Late remission
associated with
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Table 1 (Continued )
Study Recruitment
period
Inclusion
criteria
Exclusion
criteria
Type of study Setting n Epilepsy
type
Follow up Method of
follow-up
n with
outcome
Outcomes Prognostic
factors identiﬁed
10.8% achieved
late remission
(remission after
>24 months after
start of AED)
Increased number of
partial seizures
Odds ratio (OR) of late
remission
2.7 for patientswith 2–
5 partial seizures
6.7 in patients with >5
partial seizures
Age, aetiology, EEG,
neurologic/psychiatric
abnormality, disease
duration, seizure types
not associated with
outcomes
Lindsten
et al.45
1985–87 Diagnosis of
epilepsy
Provoked
seizures
Retrospective Clinic 107 Mixed 1–12 years
(range)
Chart review 107 1 year remission
68%
Seizures in the ﬁrst
year after starting AED
predictive of never
achieving 1 year
remission
3 year remission
64%
Not predictive of
remission:
5 year remission
58%
Age at diagnosis,
Seizure type,
Etiology
EEG
Schiller and
Najjar82
1999–2004 Commencing
AED therapy
None stated Prospective Clinic 478 Mixed 1.5 to 7.5 Clinical review 478 Seizure free rates
dropped with
sequential failure
of AED
Response to past AEDs
41.7%, after one
AED
Type of epilepsy
16.6%, after 2–5
AED
Duration of epilepsy
0% after 6–7 AED Number of seizures in
the 3 months prior to
AED initiation
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R. Mohanraj, M.J. Brodie / Seizure 22 (2013) 333–344 337less secure in the non-specialist setting.10 Such studies are also
resource intensive and very few have been conducted. Alterna-
tively those run by epilepsy specialists are open to the criticism
that they are unlikely to be population-based.
Studies of prognosis in newly diagnosed epilepsy examine the
likelihood of seizure remission with AED therapy, or the likelihood
of developing refractory epilepsy, usually deﬁned in terms of the
number of AEDs unsuccessfully tried.11,12 While failure to achieve
remission with AED therapy does not always equate to refractory
epilepsy, we feel that both outcome measures represented poor
outcomes and have included studies of remission and of refractory
epilepsy in this analysis. Seizure types, aetiology, age of onset,
duration of epilepsy and number of seizures before starting AED
treatment, history of febrile convulsions, presence of neurological,
intellectual or psychiatric co-morbidity family history of epilepsy,
electro-encephalographic ﬁndings and early response to AED
treatment are some of the variables that have been examined by a
number of authors. Their conclusions regarding each variable are
summarised below.
3. Seizure types
Some studies have suggested a signiﬁcant effect of seizure types
on prognosis. In the population based study in Rochester,
Minnesota, Annegers and colleagues found that patients with
generalised tonic–clonic and absence seizures had 80 and 85%
probability respectively of achieving remission, compared to only
65% for patients with complex partial seizures.13 Analysis of data
from two Veterans Affairs randomised control studies of AED
treatment also showed that patients with complex partial seizures
fared worst, with remission rates of 23 and 26% in the two studies
compared to 55 and 48% for patients with generalised tonic–clonic
seizures.14 These low numbers can be, in part, explained by the
inclusion of patients who had already failed their ﬁrst treatment
schedule. Smaller clinic-based studies, however, have also
supported this ﬁnding.15,16
Patients experiencing multiple seizure types also appear to
have worse outcomes in adults17–19 and children.20–22 However,
another large community based study, the UK National General
Practice Survey of Epilepsy (NGPSE), found only a modest effect of
seizure type on prognosis.23–25 Recent evidence implicates seizure
clusters as being associated with poorer prognosis.26 Analysis of
these data overall, however, suggests that the effect of seizure
types is less important than other factors including early response
to treatment in determining eventual outcome.
4. Aetiology
Epilepsies relating to structural brain abnormalities are less
likely to enter remission compared that occurring in patients with
structurally normal brains. This is manifest as a lower remission
rate for symptomatic epilepsies (both partial and generalised)
compared to idiopathic epilepsy syndromes in children.16,27–31 The
nature and location of the underlying structural abnormality can
also affect the likelihood of response to treatment. Semah and
colleagues found that in 2200 treated patients referred to a
specialist epilepsy service in France, those with temporal lobe
epilepsy were over represented compared to other types of
localisation related epilepsy.32 Analysis of 550 patients with
localisation related epilepsy in Glasgow also reported worse
remission rates in patient with hippocampal sclerosis than in focal
epilepsies due to other causes.33 However, many patients included
in these analyses did not have newly diagnosed epilepsy, and so
could be expected to have a substantially worse prognosis than
found in similar studies in newly diagnosed populations.34 Many
patients with substrates for epilepsy often regarded as invariablybeing associated with drug resistance, such as hippocampal
sclerosis, can have a good outcome and so may never be reviewed
at a specialist service.35,36
The identiﬁcation of well deﬁned electro-clinical syndromes
can allow more accurate assessment of prognosis. This is more
pertinent to paediatric cases, where epilepsy syndromes are
generally better deﬁned. A detailed analysis of all published
predictive factors in each epilepsy syndrome is beyond the scope of
this article, only a few prominent examples will be touched upon.
In their meta-analysis of studies on childhood absence epilepsy,
Bouma and colleagues found that signiﬁcant heterogeneity existed
between various cohorts in inclusion criteria and deﬁnition of
remission.37 As a result the reported remission rates ranged from
21% to 89%. Development of tonic–clonic seizures was associated
with a reduced chance of remission (35%), compared to absence
seizures only (78%), however, prognosis could not be predicted
early on. Other studies have identiﬁed myoclonic jerks, eyelid or
perioral myoclonia and presence of atypical EEG patterns as
predictive of a poor prognosis in childhood absence epilepsy and
subsequent evolution into juvenile myoclonic epilepsy (JME).38,39
Analysis of JME cohorts suggest that endophenotypes are
important in determining prognosis, with good control of seizures
with AED treatment but high rate of recurrence on withdrawal of
medication.40,41
4.1. Age at onset
Some studies in children suggest that onset of epilepsy before
the age of 12 months is a poor prognostic factor.28,30,42 Berg and
colleagues found that prognosis improved with increasing age, and
that this effect was not restricted to the ﬁrst year of life.43 However,
studies that included patients of all ages did not demonstrate a
consistent effect of age at onset on prognosis.13,25 Multivariate
analyses of prognostic factors in children44 and in adults15,45 have
found no independent correlation of age at onset with prognosis. It
is likely that any differences are a reﬂection of the epilepsy
syndromes that are prevalent among the various age groups.
Mixed cohorts of various epilepsy syndromes cannot reﬂect the
effect of individual syndromes on prognosis.
In developed countries, the highest incidence of epilepsy is in
older patients.46 These present with epilepsy as a consequence of a
variety of acquired brain disorders, including cerebrovascular
disease and neurodegeneration. Analysis of the Glasgow cohort of
newly diagnosed epilepsy suggested that outcomes were generally
better in patients aged over 65 years at the onset of epilepsy.47
Possible explanations include lack the neuronal plasticity needed
for the development of pharmacoresistance and reduced likelihood
of genetic factors adversely affecting prognosis.
5. Duration of epilepsy and number of pre-treatment seizures
Many studies have examined the impact of the number of
seizures and the time from onset of epilepsy to starting AED
treatment on prognosis. An important question for physicians is
whether treating patients early, thereby minimising the number of
subsequent seizures, will lead to improved outcomes. This is
intricately linked to the question of whether drug resistance
develops as a result of repeated seizures. The concept that
‘‘seizures beget seizures’’ was introduced by Gowers in the 19th
century48 and reinforced by the writings of Rodin in the 1960s.49 A
long history and high numbers of pre-treatment seizures were
thought to correlate with a poor outcome. This view was supported
by Reynolds and colleagues in the early 1980s and early treatment
of seizures was considered key to preventing the emergence of
drug-resistant epilepsy.50
Table 2
List of studies of outcomes in paediatric epilepsy. Studies from the same population have been grouped together.
Study Recruitment
period
Inclusion
criteria:
Exclusion criteria: Type of study Setting n Epilepsy
type
Follow up Method of
follow-up
n with
outcome
Outcomes Prognostic
factors
Arts et al.69 1988–92 Newly
diagnosed
epilepsy
None stated Prospective Clinic 494 Mixed 2 years Structured
review
466 31% poor
outcome
Intake variables
associated with poor
outcome
(Did not achieve 6
m remission by 2
years)
Number of seizures
Seizure types
Aetiology
Arts
et al.98
1988–92 Diagnosis of
epilepsy made
in the study
period
Panel judged not
epilepsy
Prospective Clinic 494 Mixed 5 years Active follow up
at 6 months and
2 years
466 345 (76%) in
terminal
remission>1 year
at 5 yrs FU
Aetiology, history of
febrile seizures and
age (at study entry)
Postal
questionnaire
290 (64%) >
2years
Sex, aetiology, post
ictal signs, history of
febrile seizures, and
remission at 6 months
65 (14%) no
seizures since
start of follow up
At 6 months
108 (24%) with
TR<1 year at 5
years, 27
intractable
Geerts
et al.22
1988–92 As above As above Prospective Clinic 415 Mixed 14.8 years
mean
Structured
review for 5
years
413 Five-year
terminal
remission (TR)
was reached by
71% of the cohort.
Course during
Associations with
failure to achieve
terminal remission
Postal
questionnaires
at year 10 and
15
Non-idiopathic
etiology
Febrile seizures
No 3 month remission
Early intractability
Camﬁeld
et al.64
1977–85 Children with 2
or more
unprovoked
seizures in the
recruitment
period
Myloclonic,
absence, tonic
seizures
Prospective Community 479 Mixed 2–12 years
(median not
stated)
Chart review 479 70% seizure free
and attempted
drug withdrawal
No effect of number of
pretreatment seizures
on prognosis for
seizure control, up to
10 pre treatment
seizures
Follow up
available 2–12
years
Progressive brain
disease
Contact with
primary care
physician
70% seizure free
after drug
withdrawal
Unknown
pretreatment
seizure number
More patients
suffering >10 pre
treatment
seizures likely to
have complex
partial seizures
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No difference
between patients
suffering up to 10
pretreatment
seizures and
those suffering
fewer
Camﬁeld
et al.99
1977–85 Children with 2
or more
unprovoked
seizures in the
recruitment
period
Myloclonic,
absence, tonic
seizures
Prospective Community 417 Mixed 92 =/ 26
months
Chart review 417 61% seizure free
on ﬁrst drug and
withdrew
medication
Presence of
neurological deﬁcits
and complex partial
seizures associated
with failure of ﬁrst
AED
Follow up
available 2–12
years
Progressive brain
disease
Contact with
primary care
physician
Only 41% of those
failing ﬁrst AED
became seizure
free with second
AED
Unknown
pretreatment
seizure number
29% of those
failing ﬁrst AED
developed
refractory
epilepsy
Ma et al.100 2000–2004 Children
diagnosed with
epilepsy in the
study period
None stated Retrospective Clinic 520 Mixed 12–75
months
(range)
Chart review 520
(89%)
344 seizure free
with ﬁrst drug
Patients with
symptomatic epilepsy
(60.3%)
Cryptogenic epilepsy
(61.5%)
Less likely to become
seizure free
Idiopathic epilepsy
(73.8%)
Ollivier
et al.101
2000–2008 CAE treated
with Valproate
Brain disorders
apart from
developmental
delay and ADHD
Retrospective Clinic 235 CAE treated
with
valproate
Not stated Chart review 180 58.3% achieved
seizure freedom
Generalised tonic
clonic seizures
High frequency of
seizures (>10/day) at
diagnosis
Younger age at
diagnosis
- associated with
failure to respond to
VPA
Berg et al.31 1993–97 Diagnosis of
epilepsy in the
recruitment
period
Diagnosis of
epilepsy made
prior to study
period by non
participating
physician
Prospective Community 885 Mixed 5 years
median
Active follow up 613 60 (10%)
intractable
(failure of 2 AEDs,
>1 sz per month)
Symptomatic/
cryptogenic
generalised
syndromes most likely
to develop IE
Berg et al.44 Panel of
neurologists felt
diagnosis of
epilepsy unlikely
34.6% with
cryptogenic /
symptomatic
generalised
Initial seizure
frequency
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Table 2 (Continued )
Study Recruitment
period
Inclusion
criteria:
Exclusion criteria: Type of study Setting n Epilepsy
type
Follow up Method of
follow-up
n with
outcome
Outcomes Prognostic
factors
Berg et al.102 Communication
and geographical
factors limiting
follow up
2.7% of idiopathic Focal EEG slowing
10.7% with other
loc rel
Acute symptomatic /
neonatal status
epileticus bad
8.2% oc
unclassiﬁed
epilepsy
Age of onset 5–9 years
good
Total number of
seizures, / febrile
status no increased
risk
Oskoui
et al.21
1991–2000 Recurrent
unprovoked
seizure
Single seizures Retrospective Clinic 240 Mixed 55 months
(mean)
Chart review 197 52.6% were in
remission
Factors predictive of
intractability
Age 2–17 Seizures starting
out with age range
12.8% had a poor
outcome
(recurrent
seizures on
therapeutic
antiepileptic drug
levels within 6
months prior to
the ﬁnal
assessment)
Multiple seizure types
(hazard ratio 6.5)
Minimum 2
years follow
up
6.9% were
intractable (more
than one seizure/
month over 1 year
with failure of
three or more
anticonvulsants)
Mental retardation at
onset (hazard ratio 7.2)
Seizure recurrence in
the ﬁrst 6 to 12months
of treatment (hazard
ratio 70)
Sillanpaa &
Schmidt90
1965–2008 Age 15 or
less
None Prospective Community
based
150 Mixed 11–42 years,
median 40
years
Structured
review
144 67% terminal
remission
Weekly seizure
frequency in the ﬁrst
year on treatment
2 or more
seizures
Living in
deﬁned
geographical
area
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and mossy ﬁbre sprouting in the hippocampus, which in turn can
reinforce their production forming excitatory recurrent cir-
cuits.51,52 Cross-sectional magnetic resonance imaging (MRI)
studies have demonstrated smaller hippocampal volumes ipsilat-
eral to the seizure focus in patients with temporal lobe epilepsy
and uncontrolled seizures.53,54 The degree of hippocampal volume
loss was related to the duration of epilepsy. Longitudinal studies
employing repeat MRI scans have demonstrated progressive
hippocampal and temporal neocortical volume loss and have
suggested that neuronal loss can be correlated to number of
seizures.55,56 Prevention of repeated seizures in this setting by
effective drug treatment could theoretically prevent neuronal
apoptosis and synaptic reorganisation, which may be responsible
for further seizures and thereby the emergence of drug resistance.
On the other hand, studies in patients who have suffered
seizures for several years, sustaining 100 or more generalised
seizures before coming to medical attention have shown that a
similar proportion go into remission as patients treated early after
only a few seizures.57Moreover, treatment with AEDs after the ﬁrst
unprovoked seizure has been shown not to affect the long-term
outcome, in spite of preventing seizures in the short term.58–61
Several groups have shown a relationship of high initial seizure
frequency with poor outcome.18,27,49,62–66 However, detailed
analyses of data from observational studies have suggested that
this is true only for patients suffering complex partial seizures.67
This would imply that the epileptogenic process responsible for the
high frequency of complex partial seizures is inherently pharma-
coresistant, and supports the view that the prognosis of each
epilepsy syndrome may be a characteristic of that speciﬁc
disorder.68
6. Concomitant morbidity
In their landmark population based study of patients with
epilepsy in Rochester Minnesota, Annegers and colleagues found
that patients who had epilepsy as a result of presumed perinatal
cerebral insult, manifesting as physical and intellectual disability
had only 46% probability of achieving seizure control, compared to
74% for patients with idiopathic epilepsy and those with epilepsy
due to postnatally acquired lesions.13 Early clinic based studies
also supported this notion in adults.15 Subsequent studies,
especially in children, have demonstrated that the presence of
neurological deﬁcit, especially associated with intellectual im-
pairment, is indicative of a poorer prognosis.20,29,44,69 However,
studies that include all age groups and predominantly adult
patients have not supported such an association. The NGPSE and
Glasgow cohorts showed no signiﬁcant effect of neurological or
intellectual deﬁcits on prognosis25,66
Psychiatric problems are more frequent in patients with
epilepsy. There is evidence to support a close relationship in the
pathogenesis of epilepsy and depression.70 Association of
psychiatric co-morbidity with refractory epilepsy has previously
been reported in adult patients.15 In the Glasgow cohort of 780
patients with newly diagnosed epilepsy, Hitiris and colleagues
noted that the presence of prior or current psychiatric co-
morbidity was signiﬁcantly associated with failure to achieve
remission.66 Similar observations have been made following
temporal lobectomy in patients with refractory epilepsy reporting
a psychiatric history.71,72
More recently, Petrovski and colleagues demonstrated that the
presence of neuropsychological symptomatology was associated
with a worse response to treatment in patients with newly
diagnosed epilepsy.73 Other neuropsychological factors may also
be important in determining prognosis. One small clinic based
study found that patients with newly diagnosed epilepsy hadverbal memory impairment74 and that impaired memory perfor-
mance at the outset was predictive of poor outcome.16 It is
possible, therefore that the presence of a psychiatric co-morbidity
early in the course of the epilepsy points to a greater underlying
cerebral dysfunction and is, therefore, predictive of a poorer
outcome.
7. Family history of epilepsy
Studies in children31 and adults15,66 have reported an associa-
tion between family history of epilepsy and poorer prognosis. In
generalised syndromes, this could be related to the underlying
genetic mechanisms underpinning the epilepsy, which might also
be responsible for determining drug response.75 The role of genetic
factors in focal epilepsies is less clear. Genetically determined
malformations of cortical development may play a role76 as may
pharmacogenetic traits that run in families.77
8. Febrile seizures
Febrile seizures have an almost uniformly benign prognosis.
However, approximately 3% of affected infants will develop
epilepsy in later life.78 Complex febrile seizures, i.e. those that
are prolonged, focal or recur within the same day, those occurring
in children with pre-existing neurological deﬁcit, and those with a
family history of epilepsy in a ﬁrst degree relative, all confer a
higher risk of developing epilepsy. There is, of course, a well known
association between febrile seizures in infancy and the develop-
ment of hippocampal sclerosis in later life.78 Hitiris and
colleagues66 found that the febrile convulsions in infancy
predicated a poorer outcome to treatment in newly diagnosed
epilepsy as did Geerts and co-workers from the Netherlands.22
9. Electroencephalographic ﬁndings
Some studies, mainly in children, have found a correlation of
background slowing and focal spike and wave activity with a
poor outcome.16,28,44 An electroencephalogram (EEG) performed
soon after a seizure is more likely to detect such abnormalities,
and is likely to have greater prognostic value.79 Studies in adults
have not found EEG to be independently predictive of outcome
after adjusting for other factors.15,45 Thus, in adults, the
prognostic value of routine interictal EEG examination has not
been established.
10. Response to ﬁrst drug
Several studies have found the response to the ﬁrst AED to be
the strongest predictor of long-term outlook in adults and
children.27,64,80–82 Patients whose seizures continue despite
adequate doses of an appropriate AED have a lower chance of
subsequent seizure remission, compared to those who are unable
to do tolerate the initial AED, and are tried on an alternative agent.
Kwan and Brodie reported that only 11% of patient who failed
initial monotherapy due to lack of efﬁcacy subsequently became
seizure free, compared to 41% of those who failed due to intolerable
adverse effects and 55% of those who experienced an idiosyncratic
adverse effects.80 If the ﬁrst AED is unsuccessful, subsequent AED
regimes have a declining likelihood of success. In an analysis of 780
patients diagnosed and treated for epilepsy in Scotland, the
authors found that the response rate to the ﬁrst, second and third
AED was 50.4, 10.7 and 2.7%, respectively.65 More recently
responses have been demonstrated in a few patients up to the
seventh regimen.12,82 The recently published International League
against Epilepsy deﬁnition of drug-resistant epilepsy recommends
that failure to gain seizure control for at least one year with the ﬁrst
R. Mohanraj, M.J. Brodie / Seizure 22 (2013) 333–3443422 tolerated, appropriately chosen and used AED schedules
(whether as monotherapy or in combination) should prompt
referral for specialist review for conﬁrmation of the diagnosis for
seizure and/or syndrome classiﬁcation and, if appropriate, for
consideration of epilepsy surgery.83
Some authors have suggested that this view might be unduly
pessimistic and that further drug trials may still result in
worthwhile improvements in seizure control for a proportion
of patients. Callaghan and colleagues studied 246 patients who
met the above deﬁnition of drug resistant epilepsy prospectively
for 3 years, and reported a 14% 6-month remission rate
(approximately 5% per year) with further drug therapy alone.84
Luciano and Shorvon found that in a population of patients with
refractory epilepsy, addition of a new AED resulted in seizure
freedom in 16%.85 Many of these patients however, will
subsequently relapse.11,12,86,87
Good early response to AED treatment is not always sustained
in the long term. Analysis of the Glasgow cohort found that 10.4% of
patients entering remission had relapse of seizures, and 5% went on
to develop drug resistant epilepsy.65 Other hospital based series
have reported the phenomenon of seizure relapse following an
initial period of good response to AEDs and eventual development
of drug resistant epilepsy. Following up a clinic population of 256
patients who had been seizure free for a minimum of 12 months,
Schiller reported that 40% of patients had suffered seizure relapse
by 5 years and 23% met the criteria for drug resistant epilepsy.11
The number of AEDs failed due to lack of efﬁcacy and duration of
epilepsy for more than 5 years before entering remission were
identiﬁed as risk factors for relapse and subsequent development
of refractory epilepsy.
While most patients who respond to AED treatment will do so
early, failure to do so does not indicate a uniformly poor prognosis.
In the Glasgow series, of 780 newly diagnosed epilepsy patients,
245 (31.4%) became seizure free immediately after starting AEDs,
achieving 12 months seizure freedom by one year of treatment, a
further 217 patients also achieved the same outcome over the rest
of the follow up.65 A retrospective survey of 352 newly diagnosed
patients from 2 epilepsy clinics in Italy reported that 56.2% entered
2 year remission immediately on starting treatment, but a further
proportion achieved remission with each successive year of follow
up, rising to a cumulative 2 year remission rate of 79% by 10 years
of follow up.88
In a long term prospective study of childhood onset epilepsy,
Sillanpaa and Schmidt reported that patients who experienced
ongoing weekly seizures during the ﬁrst year on AED treatment
were less likely to enter remission.89 However, 50% of patients
entered remission late, with a mean delay of 9 years from starting
treatment.90 The most recent analyses from the 1098 patients with
newly diagnosed epilepsy included in the Glasgow database
divided the patient outcomes into 4 distinct groups with 37.2%
demonstrating longterm seizure freedom within 6 months of
initiating treatment, 22.4% having a delayed response but an
excellent outcome, 15.7% with a relapsing-remitting pattern and
the ﬁnal 24.8% being refractory de novo.12
11. Genetics of drug resistance
Pharmacogenetics is the study of genetic inﬂuences on the
pharmacokinetics and pharmacodynamics of medications. This
ﬁeld has expanded enormously in parallel to the strides made in
genetics technology.91 A large number of genetic markers have
been studied in patients with epilepsy to identify predictors of
efﬁcacy and adverse effects.92 Single nucleotide polymorphisms
represent the most frequently studied genetic marker to date, but
genome wide association studies are underway.77 Many studies
have focussed on genes encoding the multidrug resistance proteinMDR1 (ABCB1). This, and other similar proteins are thought to play
a role in drug resistant epilepsy by extruding AEDs from the seizure
focus. C3435T polymorphism in the ABCB1 gene has been found
associated with refractory epilepsy in some studies, but a similar
number failed to replicate this association.93 It seems unlikely that
a complex outcome such as responsiveness to AED treatment can
be fully explained by variability of a single genetic factor. It is more
likely that responsiveness to AED treatment depends on a complex
interplay of genetic and environmental inﬂuences.94
12. Conclusions
Approximately one in three of patients diagnosed with epilepsy
will fail to achieve lasting remission of seizures with AEDs
treatment despite the global introduction of more than 12 new
AEDs over the past 20 years.68 These patients continue to suffer the
physical, psychological and social consequences of intractable
seizures and adverse effects from an escalating drug burden. They
also place a strain on health care resources the world over.95While
there is a clear need for new AEDs with novel mechanisms of
action, there is also a need to target available treatments, especially
epilepsy surgery, more effectively. Early identiﬁcation and
prediction of patients likely to be unresponsive to initial drug
therapy will allow earlier specialist intervention. Advances in
cerebral imaging and molecular biological techniques have
allowed a greater insight into the mechanisms underlying seizure
generation and propagation. However, this knowledge is far from
complete. The basic mechanisms of drug resistance in epilepsy also
remain largely unclear.
Epidemiological data over the years have identiﬁed several
factors that correlate with a poor prognosis in children and adults,
although some of this data is conﬂicting. More long-term studies
are required to assess the prognosis of each epilepsy syndrome.
Pharmacogenomic studies employing more sophisticated geno-
typing and bioinformatics technologies promise greater predict-
ability of response to individual AEDs. Other possibilities include
the identiﬁcation of biomarkers for drug-resistance, such as
transcranial magnetic stimulation.96 Studies to date show that
the early response to treatment is a powerful predictor of the long-
term outlook of newly diagnosed epilepsy. Patients who do not
achieve complete seizure control with the ﬁrst two appropriate
regimens of AEDs in the ﬁrst one to two years after starting
treatment, have a relatively small chance of achieving seizure
freedom with further pharmacotherapy and may be considered to
have drug-resistant epilepsy.12 There is, therefore, an urgent
unmet need for new symptomatic treatments with improved
efﬁcacy/tolerability proﬁles and, arguably more importantly,
disease-modifying approaches that will prevent or ameliorate
the processes underpinning epileptogensis.97
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